4C Biomed Israeli Company

4C Biomed combines cutting-edge science, real-world clinical insights and unique autologous cell systems (i.e. cancer and immune cells from the same patient) to drive the development of immuno-oncology therapies. Its lead drug is in a stage of IND-enabling studies and is planned to enter clinical Phase I in 2025.